Congestive Heart FailureNCT02047422
A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)
A study testing Furosemide, metolazone and furosemid/spironolactone in people with Congestive Heart Failure, run by Yonsei University.
Trial summary
To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Congestive Heart Failure
- What is being tested?
- Furosemide, metolazone and furosemid/spironolactone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jan 2014to Feb 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- dyspnea at rest or minimal activity
- tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray
Who cannot join
- hospitalization for acute heart failure decompensation
- cardiogenic shock (Systolic Blood Pressure < 80mmHg)
- Need or plan for renal replacement therapy (dialysis, kidney transplant)
- serum creatine level > 2.5mg/dl
- serum potassium (K+) > 5.5mg/dl
- Age > 80 years old or poor compliance patients
Show all 9Show fewer
- allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics
- life expectancy < 6 months (e.g. metastatic malignancy, liver cirrhosis)
- pregnancy or women at age of childbearing potential
About this study
To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients
- Conditions
- Congestive Heart Failure
- Being tested
- Furosemide, metolazone, furosemid/spironolactone, metolazone/spironolactone
- Keywords
- Heart failure, diuretics, kidney, glomerular filtration rate
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FurosemideDrug
furosemide (doubling previous furosemide dose)
metolazoneDrug
metolazone (add 2.5mg qod)
furosemid/spironolactoneDrug
spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
metolazone/spironolactoneDrug
no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
| Study group | Role | What they receive |
|---|---|---|
| Add furosemide/no spironolactone | Experimental | Not described Receives: Drug: Furosemide |
| Add metolazone/no spironolactone | Experimental | Not described Receives: Drug: metolazone |
| Add furosemid/spironolactone | Experimental | Not described Receives: Drug: furosemid/spironolactone |
| Add metolazone/spironolactone | Experimental | Not described Receives: Drug: metolazone/spironolactone |
What is being measured
The primary outcome is the main question the study is designed to answer.
urine output change
efficacy of diuretics add-on therapy, urine output change
Measured: from admission to Hospital Day (HOD)#4
Secondary outcomes (1)
serum creatinine change
safety of diuretics add-on therapy, serum creatinine change
Measured: from admission to HOD#4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2014 (estimated)
- Study startJan 2014
- Primary completionFeb 2016 (estimated)
- Study completionFeb 2016 (estimated)
Why it stopped: One of the diuretic which is planned to be used in the study is no longer available.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Congestive Heart FailureStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02047422
- Sponsor's protocol ID
- 4-2013-0808
- Status last verified
- Sep 2016
- First submitted
- 22 Jan 2014
- Last updated
- 7 Sep 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)
- ClinicalTrials.gov ID
- NCT02047422
- Acronym / sponsor ID
- 4-2013-0808
- Conditions
- Congestive Heart Failure
- Keywords
- Heart failure, diuretics, kidney, glomerular filtration rate
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: One of the diuretic which is planned to be used in the study is no longer available.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- Jan 2014
- Primary completion
- Feb 2016 (estimated)
- Study completion
- Feb 2016 (estimated)
- First posted
- 28 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Add furosemide/no spironolactone | Experimental | Drug: Furosemide |
| Add metolazone/no spironolactone | Experimental | Drug: metolazone |
| Add furosemid/spironolactone | Experimental | Drug: furosemid/spironolactone |
| Add metolazone/spironolactone | Experimental | Drug: metolazone/spironolactone |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- dyspnea at rest or minimal activity
- tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray
Key exclusion criteria (9 listed)
- hospitalization for acute heart failure decompensation
- cardiogenic shock (Systolic Blood Pressure < 80mmHg)
- Need or plan for renal replacement therapy (dialysis, kidney transplant)
- serum creatine level > 2.5mg/dl
- serum potassium (K+) > 5.5mg/dl
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Furosemidefurosemide (doubling previous furosemide dose) | Drug | Add furosemide/no spironolactone |
| metolazonemetolazone (add 2.5mg qod) | Drug | Add metolazone/no spironolactone |
| furosemid/spironolactonespironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user) | Drug | Add furosemid/spironolactone |
| metolazone/spironolactoneno spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user) | Drug | Add metolazone/spironolactone |
Primary outcome
urine output change
Time frame: from admission to Hospital Day (HOD)#4
efficacy of diuretics add-on therapy, urine output change
1 secondary outcome
serum creatinine change
Time frame: from admission to HOD#4
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Sep 2016.
Related trials for Congestive Heart Failure
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Recruiting
Evaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction
Heart Failure
Recruiting
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
Enrolling by invitation
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
Heart Failure, Transplant; Failure, Heart
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Furosemide, metolazone and furosemid/spironolactone in people with Congestive Heart Failure, run by Yonsei University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 7 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
urine output change (time frame: from admission to Hospital Day (HOD)#4). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2016.